About Immunic, Inc.

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Employees: 100
Price: $9.48
Previous close: $9.37
Market capitalization: $127.63M
Volume: 662,384
P/E ratio: -1.95
52-week low: $5.06
52-week high: $17.43

Additional performance and financial-statement views load in the interactive application.

Market information is provided for research and visualization and is not investment advice.